The Maryland Stem Cell Research Commission announced it will grant $4,165,325 in award funding to innovative research that will strengthen and advance stem cell treatments and technologies in Maryland.
Governor Larry Hogan today announced a new Maryland Cancer Moonshot Initiative to expand and accelerate cancer detection, screening, prevention, treatment, and research in the state. The state is committing $216 million in investments as a down payment to jumpstart this far-reaching initiative to save lives, including the first ever comprehensive cancer center in Prince George’s County.
BioBuzz has been reporting on myriad medtech university system spinouts and maturing companies from the Baltimore area for a number of years; we’ve featured a number of exciting and promising individual companies. However, as we’ve stepped back a bit to examine more recent Baltimore biohub developments, it’s become clear that there is an unmistakable groundswell of medtech activity that’s transforming the Baltimore life sciences sector.
The Baltimore biotech ecosystem is thriving. And new, big and bold life sciences development projects are in the works, leading many to project Charm City as the next sector of the BioHealth Capital Region (BHCR) to boom.
A group of Johns Hopkins University scientists has collaborated with more than 100 researchers around the world to assemble and analyze the first complete sequence of a human genome, two decades after the Human Genome Project produced the first draft.
The work is part of the Telomere to Telomere (T2T) consortium, led by researchers at the National Human Genome Research Institute (NHGRI); University of California, Santa Cruz; and University of Washington, Seattle.
Johns Hopkins contributed key research to the effort to decipher our DNA—which has remained a mystery despite the initial progress 20 years ago. The revelations are expected to open new lines of molecular and genetic exploration while providing scientists with a clearer picture of how DNA affects the risks of diseases, and how genes are expressed and regulated.
A new cell and gene therapy point of care treatment facility at Johns Hopkins University, expected to open in 2023, has boosted both the state’s importance, as well as Baltimore’s importance as a lynchpin in the cell and gene therapy industry.
‘Johns Hopkins Technology Ventures has become an invaluable and essential campus resource.’
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and The Johns Hopkins University, today announce the next phase of their collaboration. This new phase involves construction of a cell and gene therapy processing facility for point of care treatment of patients at Johns Hopkins which is planned to start in Q2 2022 and is expected to be operational in Q2 of 2023.
Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.
Longeviti Neuro Solutions, developer of the first low-profile intracranial devices that meets the functional and reconstructive needs of brain surgery patients, recently announced that it was granted a 510(k) clearance by the U.S Food and Drug Administration (FDA) for ClearFit® OTS (off-the-shelf).
